Commonwealth Bank of Australia Raises Position in Mallinckrodt PLC (MNK)
Commonwealth Bank of Australia increased its holdings in Mallinckrodt PLC (NYSE:MNK) by 1,572,207.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 204,400 shares of the company’s stock after acquiring an additional 204,387 shares during the quarter. Commonwealth Bank of Australia’s holdings in Mallinckrodt were worth $3,811,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of the stock. Credit Agricole S A bought a new position in shares of Mallinckrodt in the 2nd quarter worth about $1,268,000. Dimensional Fund Advisors LP increased its stake in shares of Mallinckrodt by 8.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,422,787 shares of the company’s stock worth $82,531,000 after acquiring an additional 345,385 shares in the last quarter. Chicago Equity Partners LLC bought a new position in shares of Mallinckrodt in the 2nd quarter worth about $575,000. Janus Henderson Group PLC bought a new stake in Mallinckrodt during the 2nd quarter valued at about $237,000. Finally, Oppenheimer & Co. Inc. increased its stake in Mallinckrodt by 66.3% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 27,654 shares of the company’s stock valued at $515,000 after purchasing an additional 11,023 shares in the last quarter.
Shares of NYSE MNK opened at $33.00 on Friday. The company has a current ratio of 2.27, a quick ratio of 2.06 and a debt-to-equity ratio of 0.98. The stock has a market cap of $2.74 billion, a PE ratio of 4.66, a P/E/G ratio of 0.55 and a beta of 1.57. Mallinckrodt PLC has a 52-week low of $11.65 and a 52-week high of $39.05.
MNK has been the subject of a number of analyst reports. Cantor Fitzgerald restated a “buy” rating and set a $42.00 price objective on shares of Mallinckrodt in a research note on Tuesday, August 7th. Piper Jaffray Companies restated a “buy” rating and set a $39.00 price objective on shares of Mallinckrodt in a research note on Wednesday, August 8th. Zacks Investment Research upgraded shares of Mallinckrodt from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research note on Monday, August 27th. Morgan Stanley raised their price objective on shares of Mallinckrodt from $14.00 to $35.00 and gave the company an “equal weight” rating in a research note on Friday, August 17th. Finally, SunTrust Banks raised their price objective on shares of Mallinckrodt to $21.00 and gave the company a “hold” rating in a research note on Tuesday, June 19th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $34.35.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Further Reading: Trading Strategy
Want to see what other hedge funds are holding MNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mallinckrodt PLC (NYSE:MNK).
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.